These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16857731)

  • 1. Determining the potency and molecular mechanism of action of insurmountable antagonists.
    Kenakin T; Jenkinson S; Watson C
    J Pharmacol Exp Ther; 2006 Nov; 319(2):710-23. PubMed ID: 16857731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods.
    Ehlert FJ
    Mol Pharmacol; 1988 Feb; 33(2):187-94. PubMed ID: 2828914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of orthosteric ligands to the allosteric site of the M(2) muscarinic cholinergic receptor.
    Redka DS; Pisterzi LF; Wells JW
    Mol Pharmacol; 2008 Sep; 74(3):834-43. PubMed ID: 18552124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of allosterism in functional assays.
    Ehlert FJ
    J Pharmacol Exp Ther; 2005 Nov; 315(2):740-54. PubMed ID: 16046613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.
    Steinfeld T; Mammen M; Smith JA; Wilson RD; Jasper JR
    Mol Pharmacol; 2007 Aug; 72(2):291-302. PubMed ID: 17478612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for positive allosteric modulators: assessment of modulator concentration-response curves as a screening paradigm.
    Langmead CJ
    J Biomol Screen; 2007 Aug; 12(5):668-76. PubMed ID: 17478477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect.
    Kenakin T
    ACS Chem Biol; 2009 Apr; 4(4):249-60. PubMed ID: 19193052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the properties of allosteric and orthosteric GABAB receptor ligands after a continuous, desensitizing agonist pretreatment.
    Gjoni T; Urwyler S
    Eur J Pharmacol; 2009 Jan; 603(1-3):37-41. PubMed ID: 19109945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric properties of G protein-coupled receptor oligomers.
    Springael JY; Urizar E; Costagliola S; Vassart G; Parmentier M
    Pharmacol Ther; 2007 Sep; 115(3):410-8. PubMed ID: 17655934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor.
    Heitman LH; Ye K; Oosterom J; Ijzerman AP
    Mol Pharmacol; 2008 Jun; 73(6):1808-15. PubMed ID: 18344315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions.
    Avlani VA; McLoughlin DJ; Sexton PM; Christopoulos A
    J Pharmacol Exp Ther; 2008 Jun; 325(3):927-34. PubMed ID: 18322151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric and orthosteric binding modes of two nonpeptide human gonadotropin-releasing hormone receptor antagonists.
    Sullivan SK; Brown MS; Gao Y; Loweth CJ; Lio FM; Crowe PD; Struthers RS; Betz SF
    Biochemistry; 2006 Dec; 45(51):15327-37. PubMed ID: 17176055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
    Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric modulation of 5-HT(1A) receptors by zinc: Binding studies.
    Barrondo S; Sallés J
    Neuropharmacology; 2009 Feb; 56(2):455-62. PubMed ID: 18951909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors.
    Lanzafame AA; Sexton PM; Christopoulos A
    Mol Pharmacol; 2006 Aug; 70(2):736-46. PubMed ID: 16709648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data-driven analysis in drug discovery.
    Kenakin T
    J Recept Signal Transduct Res; 2006; 26(4):299-327. PubMed ID: 16818378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of dose-response curves by effector blockade and uncompetitive antagonism.
    Pennefather P; Quastel DM
    Mol Pharmacol; 1982 Sep; 22(2):369-80. PubMed ID: 6292695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allosterism and cannabinoid CB(1) receptors: the shape of things to come.
    Ross RA
    Trends Pharmacol Sci; 2007 Nov; 28(11):567-72. PubMed ID: 18029031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociation.
    Vauquelin G; Szczuka A
    Neurochem Int; 2007 Oct; 51(5):254-60. PubMed ID: 17606314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors.
    Chen Y; Goudet C; Pin JP; Conn PJ
    Mol Pharmacol; 2008 Mar; 73(3):909-18. PubMed ID: 18056795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.